The Troubled Rupee

An employee uses an electronic machine to check a rupee note inside a bank in Allahabad December 16, 2011. REUTERS/Jitendra Prakash/Files

Rupee at record low as India seen lacking options to brake fall

A top official said the government has options to stem a fall in the rupee but did not offer any specifics, turning the focus on the RBI to stem a rout that sent the rupee to record lows.  Full Article 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Slowing Down QE

Slowing Down QE

Bernanke says Fed likely to reduce bond buying this year.  Full Article 

Surveillance System

Surveillance System

India sets up elaborate system to tap phone calls, e-mail.  Full Article 

Monsoon Floods

Monsoon Floods

Death toll in Uttarakhand monsoon floods crosses 150  Full Article 

China Factory Activity

China Factory Activity

China June flash HSBC PMI hits nine-month low on weak demand.  Full Article 

FIIs and Banks

FIIs and Banks

High FII holding makes private banks vulnerable after Fed - analysts.  Full Article 

Sony's Plans

Sony's Plans

Sony CEO asks for patience as shareholders press on spinoff plan.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

MARKET EYE-Glenmark gains on USFDA nod for diarrhoea drug

Related Topics

Stocks

   
Horsing Around

Horsing Around

Snapshots of horses on different courses.  Slideshow 

» Click here for more slideshows

Tue Jan 1, 2013 1:39pm IST 

* Shares in Glenmark Pharmaceuticals gain 2.5 percent
after U.S. health regulators approved Salix Pharmaceuticals
Ltd's drug to treat diarrhoea in HIV/AIDS patients on
qantiretroviral therapy, a combination of medicines used to
treat HIV infection. 
* Glenmark will be the active pharmaceutical ingredients
supplier for the drug to Salix in regulated markets.
* An international arbitrator ruled in August 2012 that Glenmark
Pharmaceuticals has the right to sell its HIV-associated
diarrhoea drug Crofelemer in 140 countries. 
* Edelweiss in a report says, "The overall potential market for
Crofelemer is anticipated at $300 million-$500 million and peak
potential revenue for Glenmark, from API supply, could be $15
million-$20 million per annum."

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
India Markets
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.